Complex Monitoring of Biochemical and Radionuclide Parameters in Patients with Metastatic Renal Cell Carcinoma during Immunotherapy.
Conclusions: All mRCC patients after nephrectomy were recommended to undergo biochemical monitoring with inclusion of TGF-β and IL-17A, as well as radionuclide monitoring (CRS) to determine the RF risk at an early stage.
PMID: 29201463 [PubMed]
Source: International Journal of Nephrology - Category: Urology & Nephrology Tags: Int J Nephrol Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemistry | Immunotherapy | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Renal Failure | Statistics | Study | Urology & Nephrology